Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives Consensus Rating of “Hold” from Brokerages

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) has been given an average rating of “Hold” by the seven analysts that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $3.75.

Several research analysts have weighed in on HOWL shares. Wall Street Zen upgraded shares of Werewolf Therapeutics to a “sell” rating in a research report on Saturday, August 1st. Weiss Ratings downgraded shares of Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 16th.

Werewolf Therapeutics Stock Down 3.8%

NASDAQ HOWL opened at $0.38 on Tuesday. The company has a 50-day moving average price of $0.38 and a 200-day moving average price of $0.59. Werewolf Therapeutics has a 52 week low of $0.27 and a 52 week high of $2.38. The firm has a market capitalization of $18.57 million, a P/E ratio of -0.50 and a beta of 0.29.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings data on Friday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.36. The business had revenue of $21.00 million during the quarter, compared to analysts’ expectations of $21.00 million. As a group, equities research analysts anticipate that Werewolf Therapeutics will post -1.08 EPS for the current year.

Insiders Place Their Bets

In other Werewolf Therapeutics news, Director Luke Evnin sold 107,429 shares of the business’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $0.31, for a total transaction of $33,302.99. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Ra Capital Management, L.P. sold 416,911 shares of the company’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $0.35, for a total value of $145,918.85. Following the completion of the sale, the insider owned 303,719 shares of the company’s stock, valued at approximately $106,301.65. The trade was a 57.85% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 2,513,385 shares of company stock worth $982,239. 23.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC bought a new stake in Werewolf Therapeutics during the 1st quarter worth approximately $79,000. Marshall Wace LLP purchased a new position in Werewolf Therapeutics during the second quarter valued at approximately $113,000. Qube Research & Technologies Ltd bought a new position in shares of Werewolf Therapeutics in the second quarter worth approximately $48,000. Jane Street Group LLC bought a new position in shares of Werewolf Therapeutics in the second quarter worth approximately $409,000. Finally, Bank of America Corp DE increased its stake in shares of Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after purchasing an additional 25,882 shares in the last quarter. 64.84% of the stock is currently owned by institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.